BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Core Viewpoint - BrainsWay Ltd. has made two additional strategic minority stake investments in U.S. mental health providers, bringing the total to four in 2025, aiming to enhance patient access to innovative mental health treatments and drive long-term shareholder value [1][2][5] Investment Details - BrainsWay will invest an initial $1.5 million in Heading Health, with the potential for an additional $2.5 million through three milestone-based investments [3] - The investment in Heading Health will provide BrainsWay with a minority position in the form of a preferred, annually compounding security [3] Strategic Intent - The investment strategy is designed to facilitate the growth of commercial partners while allowing BrainsWay to maintain its focus on scientific and technological advancements [4] - The partnership with Heading Health is seen as a unique opportunity to expand treatment options and improve patient lives on a large scale [5] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [6] - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [6] Heading Health Overview - Heading Health specializes in interventional psychiatry, focusing on effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression [7] - The organization employs a team of board-certified psychiatrists and advanced psychiatric nurse practitioners to deliver cutting-edge treatment options [7]